Yuhan Corporation's operating profit for the second quarter was provisionally reported to have increased by 190.1% year-on-year to 45.6 billion won. Second quarter revenue increased by 8.1% year-on-year to 555.62 billion won.
Revenue from the lung cancer treatment drug "Lecregulated" approved by the U.S. Food and Drug Administration (FDA) last year is analyzed to have contributed to the company's performance increase.
In fact, license revenue for the second quarter increased by 4502.3% year-on-year to 25.5 billion won. Revenue from overseas operations in the second quarter increased by 18.1% year-on-year to 114.8 billion won. Previously, the company announced in May that it expected to receive approximately 20.7 billion won in milestone payments from Janssen in the U.S. related to the commercialization of "Lecregulated" in Japan.
Looking at the pharmaceutical business by segment, over-the-counter medicine recorded 57.4 billion won, up 9.7% year-on-year. During the same period, prescription drugs affected by the conflict with the medical profession increased by 0.3% to 287.7 billion won.
Yuhan Corporation's cumulative revenue for the first half of the year increased by 8.2% compared to the first half of last year, reaching 1.0256 trillion won. Operating profit rose by 148.1% to 54.3 billion won.